Weekly Digest - January 2026
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - January 2026
22 January 2026: China Isotope & Radiation Corporation signs commercial deal for Pluvicto, China’s first PSMA radioligand therapy
- China Isotope & Radiation Corporation disclosed that its subsidiary, Atom High-Tech, has entered into a commercial cooperation agreement with Novartis Pharma (Zhejiang), signaling a meaningful step forward in the commercialization of advanced nuclear medicine therapies in China
- At the center of this collaboration is Pluvicto (Lutetium [177Lu] vipivotide tetraxetan injection), the first and currently only approved PSMA-targeted radioligand therapy in China, which is used for the treatment of advanced prostate cancer and offers patients a new option to extend survival and improve quality of life
- Through this agreement, the two parties formally launch a strategic partnership around Pluvicto, combining Atom High-Tech’s long-standing, compliant operational experience in radiopharmaceuticals with Novartis’ innovative nuclear medicine portfolio to better serve clinical institutions and patients
- The collaboration is designed to deliver customized product supply and integrated solutions for Pluvicto, aiming to improve accessibility and ensure reliable delivery of this precision radioligand therapy to a broader population of prostate cancer patients across China
- China Isotope & Radiation Corporation emphasized that the agreement does not constitute a connected or notifiable transaction under Hong Kong listing rules, while underscoring its confidence that this partnership will accelerate the adoption of innovative nuclear drugs and reinforce its long-term commitment to advancing patient-centered oncology care
